Table 2 Results of repeat imaging at day 22
Rivaroxaban 10 mg bid/15 mg od | Rivaroxaban 15 mg bid/15 mg od | Rivaroxaban combined | UFH/warfarin | |
|---|---|---|---|---|
DVT patients | N = 23 | N = 24 | N = 47 | N = 12 |
Improved or normalized, n (%) | 18 (78.3) | 18 (75.0) | 36 (76.6) | 10 (83.3) |
Normalized | 4 (17.4) | 6 (25.0) | 10 (21.3) | 2 (16.7) |
Unchanged, n (%) | 4 (17.4) | 5 (20.8) | 9 (19.1) | 2 (16.7) |
Deteriorated, n (%) | 1 (4.3) | 1 (4.2) | 2 (4.3) | 0 |
Asymptomatic | 1 (4.3) | 0 | 1 (2.1) | 0 |
Symptomatic* | 0 | 1 (4.2) | 1 (2.1) | 0 |
PE patients | – | N = 28 | N = 28 | N = 7 |
Improved or normalized, n (%) | – | 27 (96.4) | 27 (96.4) | 7 (100) |
Normalized | 10 (35.7) | 10 (35.7) | 1 (14.3) | |
Unchanged, n (%) | – | 0 | 0 | 0 |
Deteriorated, n (%) | – | 1 (3.6) | 1 (3.6) | 0 |
Asymptomatic | 1 (3.6) | 1 (3.6) | 0 | |
Symptomatic* | 0 | 0 | 0 | |
DVT and PE patients | N = 23 | N = 52 | N = 75 | N = 19 |
Improved or normalized, n (%) | 18 (78.3) | 45 (86.5) | 63 (84.0) | 17 (89.5) |
Normalized | 4 (17.4) | 16 (30.8) | 20 (26.7) | 3 (15.8) |
Unchanged, n (%) | 4 (17.4) | 5 (9.6) | 9 (12.0) | 2 (10.5) |
Deteriorated, n (%) | 1 (4.3) | 2 (3.8) | 3 (4.0) | 0 |
Asymptomatic | 1 (4.3) | 1 (1.9) | 2 (2.7) | 0 |
Symptomatic* | 0 | 1 (1.9) | 1 (1.3) | 0 |